Milsaperidone (VHX-896) vs Risperidone (Uzedy)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Schizophrenia
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Uzedy)
Marketed by Teva Pharmaceutical Industries and partners
NCT03503318 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 544 participants assigned to placebo, monthly TV-46000, or every-two-month TV-46000. The hard clinical primary endpoint was time to impending relapse, and it was statistically significantly favorable for both monthly treatment (13/183 vs 53/181; p<0.0001) and every-two-month treatment (23/179 vs 53/181; p<0.0001).
Reported efficacy
Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): Time to Impending Relapse (Number of Participants With Impending Relapse) for Intent-to-treat [ITT] Analysis Set (From randomization up to 108 weeks): TV-46000 q1m 13/183 | TV-46000 q2m 23/179 vs Placebo 53/181 (met)
Result source: NCT03503318
Results for Schizophrenia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Milsaperidone (VHX-896) | Risperidone (Uzedy) |
|---|---|---|
| PANSS total, change | —Not reported | —Not posted · NCT00159770 |
| CGI-S, change | —Not reported | —Not posted · NCT00159770 |
| PANSS response | —Not reported | —Not posted · NCT00159770 |
| PSP, change | —Not reported | —Not posted · NCT00159770 |
| Relapse (% of patients) | —Not reported | 7.1% vs 29.3%−22.2 vs placeboNCT035033187 other results
|
PANSS total, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Uzedy)
- —Not posted · NCT00159770
CGI-S, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PANSS response
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Uzedy)
- —Not posted · NCT00159770
PSP, change
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Uzedy)
- —Not posted · NCT00159770
Relapse (% of patients)
- Milsaperidone (VHX-896)
- —Not reported
- Risperidone (Uzedy)
- 7.1% vs 29.3%−22.2 vs placeboNCT03503318
7 other results
- 12.8% vs 29.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 0.1% vs 0.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 13.3% vs 29.3% NCT03503318
- 7.1% vs 29.3% NCT03503318
- 12.8% vs 29.3% NCT03503318
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Milsaperidone (VHX-896): no structured comparison results are available for Schizophrenia.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Milsaperidone (VHX-896): 0 of 4 rows · Risperidone (Uzedy): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Risperidone (Uzedy) |
|---|---|
| Dropout rate | 21.3%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results22.2%q2m NCT03503318 · Phase 3 · monotherapy 22.4%q1m NCT03893825 · Phase 3 · monotherapy 24.7%q2m NCT03893825 · Phase 3 · monotherapy |
| Discontinued due to AEs | 2.2%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results1.1%q2m NCT03503318 · Phase 3 · monotherapy 0%q1m NCT03893825 · Phase 3 · monotherapy 1.2%q2m NCT03893825 · Phase 3 · monotherapy |
| Serious AEs | 4.4%q1ma NCT03503318 · Phase 3 · monotherapy show 3 more results5.6%q2m NCT03503318 · Phase 3 · monotherapy 4.7%q1m NCT03893825 · Phase 3 · monotherapy 6.8%q2m NCT03893825 · Phase 3 · monotherapy |
| Most frequent reported AEs | q1ma injection site nodule 6.6% (placebo 3.4%) insomnia 6.6% (placebo 5.6%) injection site pruritus 5.5% (placebo 2.2%) NCT03503318 · Phase 3 · monotherapy show 3 more resultsq2m injection site nodule 7.2% (placebo 3.4%) weight increased 7.2% (placebo 3.4%) injection site pain 6.7% (placebo 6.1%) NCT03503318 · Phase 3 · monotherapy |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Risperidone (Uzedy)
show 7 more results
show 1 more result
show 1 more result
show 1 more result
Bipolar Disorder
Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Bipolar Disorder pipeline
Milsaperidone (VHX-896)
Marketed by Vanda Pharmaceuticals
NCT06494397 · Phase 1 · completed
Every participant in this trial received both VHX-896 and iloperidone, just in a different order, so there is no separate group that shows what happens without VHX-896, and nobody was blinded to which drug was being given at each stage. The trial measured drug levels in the blood to compare the two products, not any change in psychiatric symptoms, and results have not been posted yet.
No aligned efficacy figure on record for this race.
Risperidone (Uzedy)
Marketed by Teva Pharmaceutical Industries and partners
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
No aligned efficacy figure on record for this race.
Results for Bipolar Disorder
There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.
Milsaperidone (VHX-896): no structured comparison results are available for Bipolar Disorder.
Risperidone (Uzedy): no structured comparison results are available for Bipolar Disorder.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Milsaperidone (VHX-896)'s landscape · Risperidone (Uzedy)'s landscape